Gonzalo Spera

541 total citations
24 papers, 176 citations indexed

About

Gonzalo Spera is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Gonzalo Spera has authored 24 papers receiving a total of 176 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Gonzalo Spera's work include Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (6 papers). Gonzalo Spera is often cited by papers focused on Breast Cancer Treatment Studies (9 papers), HER2/EGFR in Cancer Research (7 papers) and Advanced Breast Cancer Therapies (6 papers). Gonzalo Spera collaborates with scholars based in Canada, South Korea and United States. Gonzalo Spera's co-authors include Rodrigo Fresco, John R. Mackey, Jason R.B. Dyck, Edith Pituskin, Hoki Fung, D. Ian Paterson, Sara A. Hurvitz, Peter A. Fasching, Miguel Martín and Jutta Steinseifer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Gonzalo Spera

20 papers receiving 174 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gonzalo Spera Canada	6	104	89	51	48	41	24	176
Hiroki Kamata Japan	5	76 0.7×	19 0.2×	19 0.4×	16 0.3×	30 0.7×	11	168
Chiara Bolognesi Italy	4	58 0.6×	25 0.3×	53 1.0×	21 0.4×	13 0.3×	18	320
Mingchao Wang China	6	42 0.4×	26 0.3×	33 0.6×	45 0.9×	8 0.2×	13	178
Lloyd Bod France	8	74 0.7×	19 0.2×	20 0.4×	59 1.2×	9 0.2×	10	247
Daniela Fux Austria	8	39 0.4×	24 0.3×	13 0.3×	43 0.9×	7 0.2×	11	170
Irina Kerle Germany	3	166 1.6×	57 0.6×	110 2.2×	12 0.3×	15 0.4×	5	332
Yini Zhu United States	8	47 0.5×	27 0.3×	31 0.6×	31 0.6×	6 0.1×	12	188
Bao Guo Li China	4	60 0.6×	183 2.1×	50 1.0×	27 0.6×	19 0.5×	7	250
Eva Tonsing-Carter United States	4	58 0.6×	44 0.5×	33 0.6×	16 0.3×	96 2.3×	6	165

Countries citing papers authored by Gonzalo Spera

Since Specialization

Citations

This map shows the geographic impact of Gonzalo Spera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gonzalo Spera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gonzalo Spera more than expected).

Fields of papers citing papers by Gonzalo Spera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gonzalo Spera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gonzalo Spera. The network helps show where Gonzalo Spera may publish in the future.

Co-authorship network of co-authors of Gonzalo Spera

This figure shows the co-authorship network connecting the top 25 collaborators of Gonzalo Spera. A scholar is included among the top collaborators of Gonzalo Spera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gonzalo Spera. Gonzalo Spera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hendrickson, Andrea E. Wahner, Boris Winterhoff, Andrew A. Adjei, et al.. (2025). 1074P Claudin- 6 (CLDN6) is a therapeutic target in ovarian cancer (OC): Emerging results from the CATALINA 1 (CAT1) study. Annals of Oncology. 36. S678–S678.

Stroyakovskiy, Daniil, DA Yardley, Chiun‐Sheng Huang, et al.. (2025). LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes. Annals of Oncology. 36. S1559–S1559.

García-Sáenz, José Á., Gonzalo Spera, Marina Pollán, et al.. (2025). Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies. International Journal of Cancer. 157(4). 709–721. 1 indexed citations

O’Kane, Grainne M., Do‐Youn Oh, Jennifer L. Spratlin, et al.. (2024). A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).. Journal of Clinical Oncology. 42(16_suppl). 4115–4115. 2 indexed citations

O’Kane, Grainne M., Jennifer L. Spratlin, D-Y. Oh, et al.. (2024). 44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy. Annals of Oncology. 35. S22–S22. 1 indexed citations

Spratlin, Jennifer L., Sun Young Rha, Grainne M. O’Kane, et al.. (2024). A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastric cancer: Efficacy and safety analysis (BOLD-100-001).. Journal of Clinical Oncology. 42(16_suppl). 4059–4059.

Spratlin, Jennifer L., Grainne M. O’Kane, Do‐Youn Oh, et al.. (2023). Abstract CT149: BOLD-100-001 (TRIO039): a phase 1b/2a dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced colorectal cancer: interim efficacy, safety and tolerability analysis. Cancer Research. 83(8_Supplement). CT149–CT149. 4 indexed citations

Hurvitz, Sara A., Vanesa Quiroga, Yeon Hee Park, et al.. (2022). Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study. Cancer Research. 82(4_Supplement). PD13–6. 6 indexed citations

Fasching, Peter A., Aditya Bardia, Vanesa Quiroga, et al.. (2022). Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.. Journal of Clinical Oncology. 40(16_suppl). 589–589. 24 indexed citations

10.

Hurvitz, Sara A., Y.H. Park, Aditya Bardia, et al.. (2021). LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study. Annals of Oncology. 32. S1285–S1286. 13 indexed citations

11.

Spera, Gonzalo, et al.. (2019). Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy. Clinical Breast Cancer. 19(3). e468–e474. 2 indexed citations

12.

Slamon, Dennis J., Peter A. Fasching, Ravindranath Patel, et al.. (2019). NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).. Journal of Clinical Oncology. 37(15_suppl). TPS597–TPS597. 38 indexed citations

13.

Chan, Amy B. W., Gonzalo Spera, Hoki Fung, et al.. (2019). Abstract PD3-12: Central nervous system as first site of relapse in patients with HER2 positive early breast cancer treated in the BCIRG-006 trial. Cancer Research. 79(4_Supplement). PD3–12. 2 indexed citations

14.

Hurvitz, Sara A., Miguel Martín, Kyung Hae Jung, et al.. (2019). Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. Journal of Clinical Oncology. 37(15_suppl). 500–500. 4 indexed citations

15.

Spera, Gonzalo, Rodrigo Fresco, Hoki Fung, et al.. (2017). Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Annals of Oncology. 28(8). 1836–1841. 55 indexed citations

16.

Spera, Gonzalo, Rodrigo Fresco, Hoki Fung, et al.. (2017). Abstract P6-16-02: Beta-adrenergic receptor blockers (BB) and increased progression free survival (PFS) in patients with advanced triple negative breast cancer (TNBC): A retrospective analysis of the ROSE/TRIO012 study. Cancer Research. 77(4_Supplement). P6–16. 1 indexed citations

17.

Delgado, Lucı́a, et al.. (2012). Análisis de sobrevida según perfil biológico de pacientes uruguayas con cáncer de mama. SHILAP Revista de lepidopterología.

18.

Delgado, Lucı́a, et al.. (2010). Expresión tumoral de HER-2, receptores de estrógenos y de progesterona y su relación con características clínico-patológicas en pacientes uruguayas con cáncer de mama. SHILAP Revista de lepidopterología. 1 indexed citations

19.

Caronna, Roberto, Maurizio Cardi, William Arcese, et al.. (2006). Gastrointestinal surgical emergencies in patients treated for hemathological malignancies.. PubMed. 4(3). S141–5. 3 indexed citations

20.

Stentella, P, et al.. (1997). Prevention of thromboembolic complications in women undergoing gynecologic surgery.. PubMed. 24(2). 58–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact